Request Demo
Recent blog posts
Latest Hotspot
8 min read
Polatuzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Polatuzumab is a Monoclonal antibody targeting CD79B, at Clinical. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.
Latest Hotspot
8 min read
Ziftomenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ziftomenib is a Small molecule drug targeting MLL1 x menin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Revumenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Revumenib is a Small molecule drug targeting menin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Tovorafenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Tovorafenib is a Small molecule drug targeting PDPK1 x Raf kinase, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Vorasidenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Vorasidenib is a Small molecule drug targeting IDH1 x IDH2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Belzutifan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Belzutifan is a Small molecule drug targeting HIF-2α, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Berzosertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Berzosertib is a Small molecule drug targeting ATR, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Ceralasertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ceralasertib is a Small molecule drug targeting ATR, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Tuvusertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Tuvusertib is a Small molecule drug targeting ATR, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Camonsertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Camonsertib is a Small molecule drug targeting ATR, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Imlunestrant Tosylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Imlunestrant Tosylate is a Small molecule drug targeting ER, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Elacestrant hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Elacestrant hydrochloride is a Small molecule drug targeting ERα, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.